Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 91Recruiting 47Terminated 43Active not recruiting 42Withdrawn 14Unknown 10Not yet recruiting 7Suspended 2Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

TNBC 1

Interventions

zilucoplan 1toripalimab 1somapacitan 1rozanolixizumab 1pembrolizumab 1ibrutinib 1futibatinib 1exemestane 1enzalutamide 1durvalumab 1decitabine and cedazuridine drug combination 1cemiplimab 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Tamoxifen 1Robotic Surgical Procedures 1Observation 1Letrozole 1Lenalidomide 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Fulvestrant 1Folfox protocol 1Dexamethasone 1Cisplatin 1Carboplatin 1Bevacizumab 1Anastrozole 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × INDUSTRY × 130-nm albumin-bound paclitaxel × Clear all
NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Huabo Biopharm Co., Ltd.

Phase 2 Enrolling by invitation
60 enrolled
Breast

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡